News | October 13, 2022
Evonik and Phathom Pharmaceuticals partner to produce novel acid-blocker vonoprazan
Agreement strengthens Evonik’s track record as leading contract development and manufacturing organization (CDMO)
Agreement strengthens Evonik’s track record as leading contract development and manufacturing organization (CDMO)
WCK 5222 is a Super-drug which is entirely a new class of antibiotic known as "?-lactam ENHANCER".
Company creates Younger T Cells for fighting cancer using its NR2F6 technology
The study demonstrated that patients who received NONS had significant reduction in viral load within 24 hours, which was sustained over seven days of treatment.
This multicenter, open-label Phase I study is designed to assess the safety and tolerability
During the research term, Olema will contribute funding to Aurigene to facilitate ongoing discovery efforts.
In clinical trials, treatment proved more effective than other therapies evaluated
Shoreline has developed a proprietary methodology to create differentiated iNK cells for large-scale, "off-the-shelf" production
The peptide-based vaccine induces a t cell-dependent response
GRC 54276 has shown tumour cell killing ability in preclinical studies as a single agent and as well in combination with checkpoint inhibitors, making it a high-priority target in immuno-oncology
Subscribe To Our Newsletter & Stay Updated
